TEVA Stock Overview

Teva Pharmaceuticals Industries Ltd, listed on the NYSE as TEVA, is the biggest manufacturer of generic drugs in the world, offering more than 500 generic and biosimilar medications. This major player in the healthcare industry also produces a range of branded drugs that contribute to its growth.

Teva Pharmaceutical Industries had impressive results in the fourth quarter of 2024, but their predictions for 2025 were disappointing, leading to a quick drop in their stock price. The company's careful outlook for 2025 may be easier to exceed, making it an attractive option for long-term investors. Teva's development projects, such as Duvakitug and various biosimilars, present strong growth opportunities, with important milestones and possible product launches expected between 2025 and 2027.

We just released a list of the 10 stocks that performed the worst on Wednesday. In this article, we will examine how Teva Pharmaceutical Industries Limited (NYSE:TEVA) ranked among these underperformers. The stock market fell on Wednesday, with all major indices ending lower, mainly due to losses in technology stocks.

Teva's stock dropped by 14% even though their fourth-quarter earnings were better than anticipated, because their outlook for 2025 is not strong.

Teva Pharmaceutical Industries (NYSE: TEVA) saw its stock prices drop on Wednesday. This decline happened as the S&P 500 and Nasdaq Composite fell by 0.5% and 0.9%, respectively. Teva announced its earnings before the market opened on Wednesday.

Teva Pharmaceutical Industries (TEVA -13.21%) saw its shares decline on Wednesday. By 1:15 p.m., the company's stock had dropped by 13.5%.

U.S. stocks declined as trading came to a close, with the Nasdaq Composite dropping by about 1% on Wednesday.

Teva Pharmaceutical Industries Ltd, a major pharmaceutical company based in Israel, is getting ready to release its latest quarterly earnings report. This report is expected to be available before the market opens on Wednesday, January 29.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) will participate in the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025, at 11:15 AM ET. The company will be represented by Richard Francis, the President and CEO, and Eric Hughes, the Head of R&D and Chief Medical Officer. Chris Schott from J.P. Morgan will also be part of the conference call.